Vicor Free cash flow decreased by 260.6% to -$16.33M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 204.8%, from $15.58M to -$16.33M. Over 3 years (FY 2022 to FY 2025), Free cash flow shows an upward trend with a 42.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.82M | -$18.10M | -$3.37M | -$7.80M | -$11.76M | $24.00K | $10.50M | $16.18M | $14.37M | -$4.69M | $9.43M | $14.12M | $8.38M | $15.58M | $59.02M | $34.47M | $10.17M | -$16.33M |
| QoQ Change | — | -410.7% | +81.4% | -131.3% | -50.8% | +100.2% | >999% | +54.1% | -11.2% | -132.6% | +301.0% | +49.8% | -40.7% | +85.9% | +278.9% | -41.6% | -70.5% | -260.6% |
| YoY Change | — | — | -157.9% | — | — | +100.1% | +411.4% | +307.4% | +222.2% | <-999% | -10.3% | -12.7% | -41.7% | +432.3% | +526.2% | +144.1% | +21.3% | -204.8% |